Type 2 Diabetes Clinical Trial
— LEGENDOfficial title:
Comparing Two Dietary Approaches for Type 2 Diabetes: The LEGEND (Lifestyle Education About Nutrition for Diabetes) Study
This study is being completed to compare two dietary approaches for participants with type 2 diabetes. This research will test whether a very low-carbohydrate or a plate-method diet better improves outcomes for blood glucose control and body composition for patients with type 2 diabetes that follow one of these approaches for 12 months. Participants that meet screening and eligibility will be randomized to one of the two diets. In addition to the diet, study specific visits and assessments will be performed at various timepoints.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | July 31, 2025 |
Est. primary completion date | July 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of type 2 diabetes, with current HbA1c > 6.5% and < 12% (self-reported and then measured at screening) - ability to speak English (this is a group-based intervention) - ability to engage in light physical activity - willingness to be randomized to either type of diet Exclusion Criteria: - unable to provide informed consent - substance abuse, mental health, cognitive, or medical condition that would, in the opinion of the investigators, make it difficult for the individual to take part in the intervention, may alter key outcomes, or may require important diet modifications and includes conditions such as hypercalcemia or thyroid dysfunction - pregnant or planning to become pregnant in the next 12 months, or currently breastfeeding (pregnancy and breastfeeding require modifications to the intervention's dietary approaches) - current use of weight loss medications (this is likely to alter weight outcomes and may alter other measures) - history of weight loss (bariatric) surgery or plans for bariatric surgery in the next year - currently enrolled in a weight loss program or have unalterable plans to enroll in one of these programs in the next year - vegan or vegetarian - unwilling or unable to participate in study measurements and group classes - current use of systemic steroids (self-reported in screening survey; oral or IV systemic steroids excluded. Injected steroids may be permitted depending on frequency and timing of injections with regard to lab assessments (minimum of 2 weeks between injection and blood tests)) - weight above 400 pounds (weight limit for dual-energy X-ray absorptiometry (DEXA) scans) - history of multiple or recent (within the last four years) kidney stones - currently following a very low-carbohydrate diet - unwilling to stop an SGLT2 inhibitor medication if the participant were to be randomized to the very low-carbohydrate diet |
Country | Name | City | State |
---|---|---|---|
United States | University of MIchigan | Ann Arbor | Michigan |
United States | The University of California San Francisco (UCSF) | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in HbA1c | HbA1c will be measured by standard immunoturbidimetric assay methods and quality control measures at a Clinical Laboratory Improvement Amendments (CLIA) certified lab. | 0 to 12 months | |
Secondary | Change in Inflammation based on high sensitivity C-reactive protein (hsCRP) | High-sensitivity C-reactive protein will be measured with nephelometric methods utilizing latex particles coated with CRP monoclonal antibodies and standardized against a CRP reference preparation. | 0 to 12 months | |
Secondary | Change in small particle low-density lipoproteins (LDL) | 0 to 12 months | ||
Secondary | Change in high-density lipoproteins (HDL) | 0 to 12 months | ||
Secondary | Change in triglycerides | 0 to 12 months | ||
Secondary | Change in percent body weight loss | 0 to 12 months | ||
Secondary | Change in percent body fat on DEXA | This will be measured by dual-energy X-ray absorptiometry scan | 0 to 12 months | |
Secondary | Change in percent lean body mass on DEXA | This will be measured by dual-energy X-ray absorptiometry scan | 0 to 12 months | |
Secondary | Change in bone mineral density in total hip | This will be measured by dual-energy X-ray absorptiometry scan | 0 to 12 months | |
Secondary | Change in bone mineral density in lumbar spine | This will be measured by dual-energy X-ray absorptiometry scan | 0 to 12 months | |
Secondary | Change in serum procollagen type I N propeptide (s-PINP) | 0 to 12 months | ||
Secondary | Change in serum c-terminal telopeptide of type 1 collagen (s-CTX) | 0 to 12 months | ||
Secondary | Reduction in diabetes medications using medication effect score (MES) | The medication effect score is a means of assessing the overall intensity of a patient's diabetes pharmacotherapy based on potency and dosages of medications (Alexopoulos et al., 2021). | 0 to 12 months | |
Secondary | Change in HbA1c | HbA1c will be measured by standard immunoturbidimetric assay methods and quality control measures at a Clinical Laboratory Improvement Amendments (CLIA) certified lab. | 0 to 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |